← Back to headlines
Molecular Partners Reports H1 2026 Financial Results and DLL3 Radiotherapy Advancement
Molecular Partners has released its financial results for the first half of 2026, highlighting the successful advancement of its DLL3 Radiotherapy MP0712 to a higher dose level in a Phase 1/2a study.
25 Aug, 05:11 — 25 Aug, 05:11
